Search
Six Years of Data: What the Longest Esketamine Study Shows About Safety
The SUSTAIN-3 study followed 1,148 adults on esketamine nasal spray for up to six and a half years. Here is what it found on side effects, blood pressure, bladder health, thinking and lasting benefit.
Three Infusions, Eleven Days: What the Bio-K Study Found in Real-World Clinics
The Bio-K study gave three ketamine infusions to 74 people with severe treatment-resistant depression at four U.S. clinics. About half reached remission, and early response predicted who would.
Telehealth Prescribing Rules Extended Through 2026: What It Means for Ketamine Patients
The DEA and HHS extended pandemic-era telemedicine rules for controlled medications to December 31, 2026. Here is what the extension allows and what is still undecided.
What the FDA Wants You to Know About Compounded Ketamine
In October 2023 the FDA warned patients and providers about the risks of compounded ketamine, especially when taken at home without monitoring. Here is what the warning says and the questions to ask.
The Anaesthetic Much of the World Depends On
Long before ketamine was studied for depression, it was an essential anaesthetic. In hospitals with few resources there is often no affordable alternative, which is why the WHO has opposed restricting it.
One Dose After Delivery: A Trial of Esketamine to Prevent Postpartum Depression
A 2024 trial in The BMJ gave new mothers with prenatal depressive symptoms a single low dose of esketamine after childbirth. Major depression at six weeks fell from about 25% to under 7%.
Ketamine and Alcohol Recovery: What the KARE Trial Is Teaching Researchers
A UK trial paired ketamine infusions with therapy for people with alcohol use disorder. A 2026 analysis found the benefit did not depend on how intense the psychedelic experience was.
Ketamine or ECT? A Follow-Up Study Shows Who Benefits From Which
A 2024 follow-up to the ELEKT-D trial looked at 365 patients to see who did better with ketamine and who did better with ECT. Severity and setting made the difference.
When Ketamine Did Not Beat the Comparison: Lessons From the KARMA-Dep 2 Trial
A 2025 trial in JAMA Psychiatry found that adding ketamine infusions to inpatient depression care worked no better than an active comparison drug. What it means, and what it does not.
A First for Treatment-Resistant Depression: Esketamine Approved as a Stand-Alone Therapy
In January 2025 the FDA approved Spravato (esketamine) nasal spray for use on its own in adults with treatment-resistant depression. Here is what changed and what the trial showed.
Can Ketamine Microdosing Ease Postpartum Depression and Reduce Substance Cravings?
A case study of a 38-year-old physician and mother with persistent postpartum depression, and how she responded to ketamine microdosing.
Can Ketamine IV Infusions Alleviate PTSD After Prolonged Grief? Mrs. Physicist Dreamer, a 64‑year‑old widow was able to do it.
The Mechanisms Behind Ketamine’s Rapid Antidepressant Effects: A Systematic Review on Molecular Neuroplasticity
A 2022 review in Frontiers in Psychiatry explains how ketamine rapidly treats depression by enhancing neuroplasticity, synaptogenesis, and glutamate signaling.
What to Know About Microdosing: Definition, Benefits, and Risks
Microdosing involves taking tiny doses of psychedelics like LSD or psilocybin to boost mood and focus. Learn the potential benefits, risks, and what science says.
Oral Ketamine RCT in New Zealand: Significant Depression Relief with Manageable Side Effects
A New Zealand RCT of R-107 oral ketamine found significant depression relief, even in treatment-resistant cases, with mild side effects and high tolerability.
UK Slow-Release Ketamine Tablet Trial Shows Reduced Relapse in Depression: Phase 2 Results
A UK Phase 2 trial shows slow-release oral ketamine reduces depression relapse by 20% over 13 weeks, offering a convenient and scalable alternative to IV treatment.
KADS Trial Shows Rapid Suicidal Ideation Reduction with Ketamine: 88% Remission in 90 Minutes
The KADS trial found subcutaneous ketamine reduced suicidal ideation in 88% of patients within 90 minutes, offering rapid relief for treatment-resistant depression.
Ketamine for Cancer and Chronic Pain Management: Insights from Frontiers in Pharmacology
A 2020 review in Frontiers in Pharmacology supports ketamine as a fast, opioid-sparing option for cancer and chronic pain, with benefits across multiple delivery methods.
Ketamine vs. Ketorolac in Veterans: Both Reduce PTSD and Pain, Ketamine Well Tolerated
A study in U.S. veterans found both ketamine and ketorolac reduce PTSD and pain symptoms, but ketamine was better tolerated and showed lasting psychological benefits.
Repurposing Ketamine to Treat Cocaine Use Disorder: AI Prediction, Clinical Validation, and Mechanistic Insights
A 2023 study in Addiction confirms ketamine's effectiveness for cocaine use disorder using AI prediction, clinical validation, and mechanistic modeling of action.
AI-Based Study Links Ketamine to 2–4× Higher Remission in Cocaine Use Disorder
An AI-powered study shows ketamine may increase cocaine use disorder remission rates by 2–4x. Real-world data points to reduced relapse and sustained abstinence.
Ketamine and Addiction: Alpha Psychiatry 2024 Review Shows Reduced Cravings and Relapse
A 2024 review in Alpha Psychiatry shows ketamine may reduce cravings and relapse in alcohol, opioid, and cocaine addiction—especially when combined with therapy.
Systematic Review: Ketamine Shows Short-Term Relief for Depression with Enhanced Outcomes When Combined with Cognitive Behavioral Therapy
A 2023 Cureus review shows ketamine offers fast depression relief, but combining it with CBT leads to longer-lasting results, fewer relapses, and better outcomes.
Real-World Effectiveness of Repeated Ketamine Infusions for Treatment-Resistant Bipolar Depression
A 2022 real-world study shows repeated ketamine infusions reduce bipolar depression symptoms by up to 70%, with fast relief and high tolerability in outpatient care.
Ketamine-Assisted Psychotherapy for Bipolar Depression: Rapid Relief Within 40 Minutes
A clinical review shows ketamine-assisted psychotherapy delivers rapid relief from bipolar depression and suicidal thoughts—often within 40 minutes of treatment.
At-Home Ketamine via Telehealth: Large Study Shows Significant Anxiety Improvement
A 2023 study of 1,247 patients shows that at-home ketamine via telehealth reduces anxiety in over 60% of users within 4 weeks—safe, scalable, and effective.
Systematic Review and Meta-Analysis: Ketamine Provides Rapid Relief for Anxiety Disorders
A 2022 meta-analysis confirms that ketamine rapidly reduces anxiety symptoms across disorders, with effects appearing within hours and minimal side effects reported.
Ketamine for Treatment of PTSD: State of the Field Review
This 2023 field review confirms ketamine’s growing role in PTSD treatment, highlighting rapid symptom relief, biological mechanisms, and therapy integration benefits.
Ketamine Infusion Study in Patients with Comorbid PTSD and TRD: Remarkable Remission Rates
New study finds ketamine infusions yield 80% PTSD remission and 93% depression response in patients with comorbid TRD—offering rapid, life-changing relief.
Narrative Review: Ketamine as an Adjunct Treatment for PTSD
Narrative review confirms ketamine’s value as an adjunct for PTSD, helping improve therapy response, emotional regulation, and long-term symptom relief.
Ketamine for PTSD: Meta-Analysis Shows Promising Symptom Relief
New meta-analysis shows ketamine offers fast and effective symptom relief for PTSD, with benefits emerging within 24 hours and lasting several days post-infusion.
Safe, Low-Cost Ketamine: A Promising Treatment for Severe Depression
Clinical trials show that low-cost ketamine is a safe, fast, and effective treatment for severe depression—offering rapid relief and expanding global access.
KADS Trial: Subcutaneous Ketamine Proves Effective for Treatment-Resistant Depression
The KADS trial shows subcutaneous ketamine is a safe, fast, and effective option for treatment-resistant depression—offering new hope and easier access.
UNSW Low-Cost Ketamine Trial: A Game Changer for Depression Treatment
The UNSW ketamine trial shows that generic, low-cost ketamine is safe and effective for treating depression. A breakthrough for affordable global mental health care.
NEJM Study: Ketamine vs. ECT – A New Era in Treating Depression
A major NEJM trial found ketamine as effective as ECT for treatment-resistant depression—with fewer side effects and faster results. Discover what this means.
Racemic Ketamine for Depression: What 49 Clinical Trials Reveal About Its Effectiveness and Safety
Learn how racemic ketamine helps treat depression. Discover findings from 49 clinical trials on safety, effectiveness, and real-world results.
Unlocking Relief from PTSD and Chronic Pain: What AJ’s Ketamine Microdosing Journey Reveals
Discover how microdosing ketamine helped AJ overcome years of PTSD, OCD, and chronic pain. Explore this case study for insights on an emerging treatment option.
Ketamine’s Antidepressant Efficacy in MDD and Bipolar Depression: A Meta-Analytic Review
Meta-analysis confirms ketamine’s fast, lasting antidepressant effects in MDD and bipolar depression, with benefits seen in just 24 hours.
Ketamine Shows Dose-Dependent Relief for Refractory Anxiety Disorders
Ketamine reduces anxiety within 1 hour, lasting up to 7 days, with dose-dependent effects in treatment-resistant GAD and SAD patients.
Extending Ketamine’s Reach: Can Exposure-Based CBT Sustain Obsessive-Compulsive Disorder Relief?
Combining ketamine with exposure-based CBT may help sustain OCD symptom relief, per a 2016 open-label trial by Rodriguez et al.
Restoring Calm: Maintenance Ketamine Therapy Offers Hope for Severe Anxiety Disorders
Weekly ketamine injections offer lasting anxiety relief in GAD and SAD patients resistant to traditional therapies, with minimal side effects.
Dual Relief in Focus: Repeated Ketamine Infusions Ease PTSD and Depression Symptoms
Repeated ketamine infusions significantly reduce PTSD and depression symptoms in patients unresponsive to standard treatments.
Refining the Dose: Intravenous Ketamine as Adjunctive Therapy for Treatment-Resistant Depression
Ketamine at 0.5–1.0 mg/kg provides rapid relief in TRD patients, with higher efficacy than low doses, as shown in a placebo-controlled trial.
Restoring Hope: Repeated Ketamine Infusions Significantly Reduce Suicidal Ideation in Veterans with PTSD and MDD
Repeated ketamine infusions rapidly reduce suicidal thoughts in veterans with PTSD and depression, offering fast, sustained relief.
Reclaiming Calm: Ketamine’s Potential Role in Treating Resistant PTSD
Ketamine may offer rapid, short-term relief for treatment-resistant PTSD by restoring emotional balance and reducing traumatic symptoms.
Rewiring the Reward Circuit: How Ketamine Enhances Emotional Processing in Depression
Ketamine restores emotional responsiveness in depression by enhancing brain reward circuits and reducing negative emotional bias.
Rewriting the Future: Ketamine’s Promise for Treatment-Resistant Mood Disorders
Ketamine offers rapid relief for depression and bipolar disorder, reshaping psychiatric care for treatment-resistant cases.
Breaking Through in India: Ketamine Therapy Demonstrates Sustained Relief in Severe Depression
An Indian trial shows ketamine’s rapid and lasting antidepressant effects in drug-free patients with severe depression.
Stopping the Spiral: Ketamine Offers Emergency Relief for Acute Suicidal Ideation
A single IV ketamine dose rapidly reduced suicidal ideation in ER patients—88% in remission within 90 minutes, study finds.
A Promising Pattern: Meta-Analysis Reveals Strong, Sustained Antidepressant Effects of Ketamine in Treatment-Resistant Depression
A meta-analysis confirms ketamine’s fast and sustained antidepressant effects in treatment-resistant depression.
Resetting the Circuitry: Prolonged Ketamine Infusions Show Sustained Benefits for Treatment-Resistant Depression
A 96-hour ketamine infusion may offer long-term relief for treatment-resistant depression and modulate key brain circuits.
Breaking the Cycle: Repeated Ketamine Infusions Show Promise for Chronic PTSD
Repeated ketamine infusions reduce chronic PTSD symptoms fast, offering relief for those unresponsive to standard treatment.
Rewiring Hope: Ketamine and the Rise of Rapid-Acting Antidepressants
Ketamine offers fast relief for depression, reshaping psychiatric care. Explore how it inspires a new era of rapid-acting antidepressants.
Mapping Recovery: Neuroimaging Markers Predicting Ketamine Response in PTSD
fMRI reveals amygdala-vmPFC connectivity as a predictor of ketamine treatment success in patients with PTSD, enabling personalized care.
Breaking Through the Wall: Expanding Options for Treatment-Resistant Depression
Explore esketamine, psilocybin, and pramipexole as emerging treatments for depression unresponsive to traditional antidepressants.
Targeting the Depths: How Low-Dose Ketamine Offers Rapid Relief for Double Depression
A single 0.5 mg/kg ketamine infusion rapidly relieves depression and suicidality in patients with treatment-resistant double depression.
Rewiring Emotional Circuits: How Ketamine Calms Overactive Brain Regions in Depression
Ketamine reduces subgenual cingulate cortex hyperactivity, easing anhedonia in major depression with fast, targeted neural effects.
Restoring Balance: Dose-Dependent Effects of Ketamine on Depression in PTSD-Resistant Veterans
Ketamine improves depression in PTSD-resistant veterans, with rapid, dose-dependent effects but limited impact on core PTSD symptoms.
Rewiring Consciousness: How Ketamine Reorganizes Neuronal Activity in the Brain
Ketamine triggers a brain-wide shift in neuronal activity, offering insights into dissociation, consciousness, and mental health treatment.
Productivity and Performance: Nutrition Hacks for Busy Professionals
Boost energy, focus, and performance with these science-backed nutrition tips designed for high-performing, time-strapped professionals.
Antidepressant, Mood-Stabilizing, and Procognitive Effects of Very Low Dose Sublingual Ketamine in Refractory Depression: A Deep Dive into New Possibilities
Explore how very low dose sublingual ketamine improves mood, cognition, and sleep in treatment-resistant unipolar and bipolar depression.
Ketamine Assisted Psychotherapy (KAP): A Comprehensive Review of Clinical Outcomes and Patient Demographics
Explore how Ketamine Assisted Psychotherapy (KAP) improves depression, anxiety, and PTSD in real-world clinical settings.
Ketamine Dose Study: Exploring Its Impact on Treatment-Resistant PTSD in Veterans
Study explores ketamine’s antidepressant effects in veterans with PTSD, highlighting dose, safety, and clinical implications.
NAD+ IV Therapy Benefits: A Complete Guide to Anti-Aging Therapy
Explore the full benefits of NAD+ IV therapy for aging, energy, brain function, and metabolism—all backed by modern science.
Science and Lifestyle Strategies for Healthy Aging
Discover science-based strategies to support healthy aging, from diet and sleep to hormones, stress, and brain health.
Hangover Survival Guide: Causes, Remedies, and Impact on Health
Learn what causes hangovers, how to treat them, and the health risks of repeated episodes. Expert-backed tips for fast, effective relief.
Unlocking Psychedelics: How Celebrities Are Rewriting the Narrative
Stars like Elon Musk and Amanda Feilding are reshaping how we view psychedelics—from stigma to science, safety, and mental health.
Ketamine for Mental Health: A Closer Look at Its Safety Compared to Traditional Medications
Ketamine offers rapid relief for depression with fewer side effects than SSRIs or benzos—find out how safe it really is in clinical use.
At-Home Sublingual Ketamine Telehealth: Expanding Access to Effective Mental Health Treatment
Sublingual ketamine via telehealth cuts anxiety and depression fast. Study shows high safety, strong results for at-home mental health care.
Ketamine Frequency Study: A New Path Forward in Treating Resistant Depression
IV ketamine, twice or thrice weekly, offers rapid and lasting relief for treatment-resistant depression. A major study shows strong results.
Ketamine for Suicidal Ideation: A Fast-Acting Intervention Backed by Science
A single IV dose of ketamine can reduce suicidal ideation in hours, offering rapid relief in crisis. Backed by robust clinical research.
Defying Despair: The Power of Ketamine in Suicide Intervention
Discover how IV ketamine therapy rapidly reduces suicidal thoughts and supports recovery from depression, anxiety, and emotional crisis.
Ketamine for Breaking Addiction Chains
Explore how ketamine therapy helps break addiction to alcohol, opioids, nicotine, and more by promoting brain rewiring and recovery.
Unlocking Relief: The Promise of Ketamine for Migraine Sufferers
Explore how IV ketamine therapy offers rapid, lasting relief from migraines—especially in drug-resistant or chronic migraine cases.
From Despair to Hope: Ketamine’s Impact on Postpartum Depression Recovery
Discover how ketamine therapy offers rapid, safe, and long-lasting relief from postpartum depression—ideal for new and nursing mothers.
Breaking Obsessions, Finding Freedom Ketamine Therapy for OCD Treatment
Discover how IV ketamine therapy provides fast, lasting relief from OCD—especially when traditional medications and CBT fall short.
Beyond the Nightmares Ketamine’s Role in PTSD Healing
Explore how ketamine therapy offers rapid, lasting relief from chronic PTSD—especially when other treatments have failed.
Unlocking Stability: The Ketamine Revolution in Bipolar Disorder Management
Discover how ketamine therapy offers fast, lasting relief for bipolar disorder symptoms—especially in treatment-resistant cases.
Ketamine: A New Horizon in the Battle Against Depression
Explore how ketamine offers fast, lasting relief for depression. A promising treatment for those who don’t respond to traditional meds.
Ketamine’s Breakthrough Role in Treating Anxiety Disorders: A Paradigm Shift in Psychiatric Care
Explore how ketamine therapy offers fast, long-lasting relief for anxiety when traditional treatments fall short. Backed by science.
Unlocking Hope for Chronic Depression: How Personalized Ketamine Titration Helped M&M Reclaim Her Life
Explore how tailored ketamine therapy helped M&M overcome lifelong depression and suicidal thoughts when standard treatments failed.
Transitioning from Macro-Dosing to Microdosing Ketamine for Anxiety and Mood Enhancement: The Case of RK
AbstractRK, a 51‑year‑old man with lifelong anxiety, depression, and ADHD, experienced worsening anxiety and dissociative...
Ketamine Infusion for Obsessive-Compulsive Disorder.
Bloch MH. Ketamine Infusion for Obsessive-Compulsive Disorder. ClinicalTrials.gov. 2014 June; https://clinicaltrials.gov/study/NCT01349231 Highlights: In a placebo-controlled study...
Efficacy of intravenous ketamine for treatment of chronic posttraumatic stress disorder.
Highlights: Objective: To test the efficacy and safety of a single intravenous subanesthetic dose of ketamine...
Rapid antidepressant effects of repeated doses of ketamine compared with electroconvulsive therapy in hospitalized patients with major depressive disorder.
Ghasemi M, Kazemi MH, Yoosefi A, Ghasemi A, Paragomi P, Amini H, Afzali MH. Rapid...
Augmentation of response and remission to serial intravenous subanesthetic ketamine in treatment resistant depression.
Shiroma, Johns et al. Augmentation of response and remission to serial intravenous subanesthetic ketamine in...
Randomized controlled crossover trial of ketamine in obsessive-compulsive disorder: Proof-of-concept.
Rodriguez, C. I., Kegeles, L. S., Levinson, A., Feng, T., Marcus, S. M., Vermes, D.,...
Transient resolution of treatment-resistant posttraumatic stress disorder following ketamine infusion.
D’Andrea, D., & Sewesll, R. A. (2013). Transient resolution of treatment-resistant posttraumatic stress disorder following...
Antidepressant efficacy of ketamine in treatment-resistant major depression: a two-site randomized controlled trial.
Murrough JW, Iosifescu DV, Chang LC, Al Jurdi RK, Green CE, Perez AM, Iqbal S,...
Rapid and Longer-Term Antidepressant Effects of Repeated Ketamine Infusions in Treatment-Resistant Major Depression.
Thomas D. Hull, Matteo Malgaroli, Adam Gazzaley, Teddy J. Akiki, Alok Madan, Leonardo Vando, Kristin...
At-home, sublingual ketamine telehealth is a safe and effective treatment for moderate to severe anxiety and depression: Findings from a large, prospective, open-labeled effectiveness trial.
Thomas D. Hull, Matteo Malgaroli, Adam Gazzaley, Teddy J. Akiki, Alok Madan, Leonardo Vando, Kristin...
OnlineTalk to ProviderCall us